US2013244222A1PendingUtilityA1

Lipoparticles comprising ion channels, methods of making and using the same

Individually held — no corporate assignee on recordPriority: Jan 26, 2006Filed: Jan 15, 2013Published: Sep 19, 2013
Est. expiryJan 26, 2026(expired)· nominal 20-yr term from priority
Inventors:Benjamin Doranz
G01N 33/6872C12N 2760/16223C12N 2760/18523C12N 2740/15023G01N 2500/10C12N 2760/16323C12N 2760/16123C12N 2710/14023C12Q 1/70C12N 2760/20223
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the use of lipoparticles, virus-like particles, and viruses. The present invention also relates to testing ion channel function and modulators of ion channels.

Claims

exact text as granted — not AI-modified
1 - 34 . (canceled) 
     
     
         35 . A composition comprising a purified virus particle, the particle comprising an external lipid bilayer, a viral core protein, a selected ion conductor, and a membrane potential sensitive dye 
     
     
         36 . The composition of  claim 35 , further comprising a test compound. 
     
     
         37 . The composition of  claim 35 , wherein the selected ion conductor is an ion channel polypeptide or an ionophore. 
     
     
         38 . The composition of  claim 35 , wherein the selected ion conductor is an activated selected ion conductor. 
     
     
         39 . The composition of  claim 35 , further comprising a ligand that binds to the ion conductor. 
     
     
         40 . The composition of  claim 35 , further comprising a salt solution, wherein the solution is at an effective concentration to activate the selected ion conductor. 
     
     
         41 . The composition of  claim 35 , wherein the membrane potential sensitive dye is di-4-ANEPPS, di-8-ANEPPS, rhodamine 421, oxonol VI, JC-1, DiSC3(5), CC2-DMPE, DiSBAC2(3), and DiSBAC4(3), DiSBAC(1)3, FMP-Blue, FMP-Red, VABSC-1, HLB 021-152, HLB 021-155, HLB 007-054, HLB 021-149, HLB 004-111, HLB 007-052, HLB 028-008, HLB 004-078, HLB 004-183, or a combination thereof. 
     
     
         42 . The composition of  claim 35 , wherein the selected ion conductor is hERG, SCN5a, KCNQ1+minK, hERG+M1RP1, M2, 5HT3a, Shaker, KCNQ2+KCNQ3 or KCNQ1. 
     
     
         43 . The composition of  claim 35 , wherein the viral core protein is an influenza core protein, HIV core protein, SIV core protein, MLV core protein, EIAV core protein, RSV core protein, VSV core protein, ALV core protein, or baculovirus core protein. 
     
     
         44 . The composition of  claim 37 , wherein the ion channel polypeptide is a viral ion channel polypeptide or a non-viral ion channel polypeptide. 
     
     
         45 . The composition of  claim 44 , wherein the non-viral ion channel polypeptide is a eukaryotic ion channel polypeptide. 
     
     
         46 . The composition of  claim 37 , wherein the ionophore is a protonophore. 
     
     
         47 . The composition of  claim 46 , wherein the ionophore is valinomycin, SQiRP, FCCP, or ionomycin. 
     
     
         48 . The composition of  claim 35 , wherein the virus particle is a virus-like particle. 
     
     
         49 . The composition of  claim 37 , wherein the virus particle is a virus-like particle. 
     
     
         50 . The composition of  claim 36 , wherein the test compound known is amantadine or rimantadine. 
     
     
         51 . The composition of  claim 35 , wherein the purified virus particle is purified from a cell.

Join the waitlist — get patent alerts

Track US2013244222A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.